Evidence map›Paper›PMID 34094833›Full record

ArticleActa pharmaceutica Sinica. B2021

Targeting BMI-1-mediated epithelial-mesenchymal transition to inhibit colorectal cancer liver metastasis.

Zhiyao Xu, Zhuha Zhou, Jing Zhang, Feichao Xuan, Mengjing Fan, Difan Zhou, Zhenyu Liuyang, Ximei Ma, Yiyang Hong, Yihong Wang and 3 more

Open access · diamondAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Acta pharmaceutica Sinica. B, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.

0numbers the graph read from it
0cells of the map it votes in
21citing papers in PubMed
1.6field-weighted citation impact, top 16% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

21 citing papers in PubMed, 32 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Review
  5. pH-responsive magnetic FeMaterials today. Bio · 2025
    Article
  6. Article
  7. Article
  8. Review
  9. Review
  10. MicroRNA-128 acts as a suppressor in the progression of gastrointestinal stromal tumor by targeting B-lymphoma Mo-MLV insertion region 1.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2024
    Article
  11. Article
  12. Article
  13. Heliyon · 2023
    Article
  14. Review
  15. Article
  16. Article
  17. Differential molecular mechanistic behavior of HDACs in cancer progression.Medical oncology (Northwood, London, England) · 2022
    Review
  18. The FAPActa pharmaceutica Sinica. B · 2022
    Article
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 4 institutions in 2 countries.

Zhiyao XuBiomedical Research Center, Sir Run Run Shaw Hospital, School of Medicine, Zhejiang University, Hangzhou 310016, China.
Zhuha ZhouDepartment of Gastrointestinal Surgery, the First Affiliated Hospital of Wenzhou Medical University, Wenzhou, 325000, China.
Jing ZhangBiomedical Research Center, Sir Run Run Shaw Hospital, School of Medicine, Zhejiang University, Hangzhou 310016, China.
Feichao XuanDepartment of General Surgery, Sir Run Run Shaw Hospital, School of Medicine, Zhejiang University, Hangzhou 310016, China.
Mengjing FanBiomedical Research Center, Sir Run Run Shaw Hospital, School of Medicine, Zhejiang University, Hangzhou 310016, China.
Difan ZhouDepartment of General Surgery, Sir Run Run Shaw Hospital, School of Medicine, Zhejiang University, Hangzhou 310016, China.
Zhenyu LiuyangDepartment of General Surgery, Sir Run Run Shaw Hospital, School of Medicine, Zhejiang University, Hangzhou 310016, China.
Ximei MaDepartment of General Surgery, Sir Run Run Shaw Hospital, School of Medicine, Zhejiang University, Hangzhou 310016, China.
Yiyang HongBiomedical Research Center, Sir Run Run Shaw Hospital, School of Medicine, Zhejiang University, Hangzhou 310016, China.
Yihong WangDepartment of Pathology, Sir Run Run Shaw Hospital, School of Medicine, Zhejiang University, Hangzhou 310016, China.
Sherven SharmaDavid Geffen School of Medicine at UCLA, and the Veterans Affairs, Los Angeles, CA 90095, USA.
Qinghua DongBiomedical Research Center, Sir Run Run Shaw Hospital, School of Medicine, Zhejiang University, Hangzhou 310016, China.
Guanyu WangDepartment of General Surgery, Sir Run Run Shaw Hospital, School of Medicine, Zhejiang University, Hangzhou 310016, China.
Sir Run Run Shaw Hospital · CNMinistry of Education of the People's Republic of China · CNUniversity of California, Los Angeles · USWenzhou Medical University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Liver is the most common metastatic site for colorectal cancer (CRC), there is no satisfied approach to treat CRC liver metastasis (CRCLM). Here, we investigated the role of a polycomb protein BMI-1 in CRCLM. Immunohistochemical analysis showed that BMI-1 expression in liver metastases was upregulated and associated with T4 stage, invasion depth and right-sided primary tumor. Knockdown

Indexed as

AKTANOVA, One-way analysis of varianceBMI-1Colorectal cancerCRC, colorectal cancerCRCLM, colorectal cancer liver metastasisEMT, epithelial–mesenchymal transitionEpithelial–mesenchymal transitionGSK-3βHDACi, histone deacetylase inhibitorHE, hematoxylin and eosinIHC, immunohistochemistryLiver metastasisLNM, lymph node metastasisNaB, sodium butyratePBS, phosphate buffered solutionPcG, polycomb-groupqPCR, real time polymerase chain reactionSnailSodium butyrateTCGA, Cancer Genome Atlas

Identifiers

PMID34094833
PMCPMC8148062
OpenAlexW3108977917

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.